Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

A cellular housekeeping process where cells break down and recycle damaged components. Declines with age and is stimulated by fasting.

What is Intermittent fasting?

An eating pattern that cycles between periods of fasting and eating. Various protocols (16:8, 5:2) are studied for metabolic, cardiovascular, and longevity benefits.

What is Zone 2 cardio?

Low-intensity aerobic exercise performed at roughly 60–70% of maximum heart rate, primarily using the aerobic energy system. Associated with mitochondrial health and longevity.

Geographic regions identified by researchers where people consistently live longer and healthier lives than average, including Sardinia, Okinawa, and Loma Linda.

What could a new cancer treatment mean for your health?

CytoDyn Inc. has announced that its CFO, Robert E. Hoffman, will present a corporate overview on May 18, 2026, during the LD Micro Invitational XVI in Los Angeles. The company is focused on advancing leronlimab, a monoclonal antibody that targets the CCR5 receptor, which could have therapeutic benefits for various cancers, including metastatic triple-negative breast cancer and colorectal cancer. This presentation will provide insights into the company’s current development strategy and future milestones.

For those interested in healthy aging and longevity, the implications of CytoDyn’s work could be significant. Leronlimab’s potential to improve immune function may not only help in the fight against cancer but could also play a role in enhancing overall health and quality of life. As research progresses, this could lead to new treatments that help people live longer, healthier lives by targeting diseases that affect aging populations.

The upcoming presentation is part of a larger conference dedicated to small-cap companies, and while CytoDyn is still in the clinical stage of development, the interest in leronlimab reflects a growing focus on innovative therapies in oncology. However, it’s important to note that the findings and benefits of leronlimab are still under investigation, and more evidence is needed to confirm its effectiveness in humans.

If you’re curious about the latest advancements in cancer treatment and their potential impact on longevity, consider following CytoDyn’s developments and similar companies in the biotech space. Staying informed could help you understand emerging therapies that may improve health outcomes in the future.

Source: globenewswire.com